Amneal Pharmaceuticals(AMRX) - 2024 Q2 - Quarterly Results

Exhibit 99.2 AMNEAL REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS ‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT U.S. FDA approval represents an exciting new long-term growth driver ‒ ® BRIDGEWATER, NJ, August 9, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today for the second quart ...